NASDAQ:CYCN Cyclerion Therapeutics (CYCN) Stock Price, News & Analysis → Reclusive millionaire’s final warning about America (From Weiss Ratings) (Ad) Free CYCN Stock Alerts $2.86 +0.07 (+2.51%) (As of 10:10 AM ET) Add Compare Share Share Today's Range$2.85▼$2.8650-Day Range$2.05▼$3.5052-Week Range$1.75▼$5.25Volume581 shsAverage Volume2,690 shsMarket Capitalization$7.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Cyclerion Therapeutics alerts: Email Address Ad Weiss RatingsReclusive millionaire’s final warning about AmericaThis crisis that's likly to begin in this country — before the election — could be bigger and more destructive than any crisis I've ever seen. That's why, no matter what you do, make sure you watch my short video and learn the three steps you need to take right now.Click here to learn how to prepare before it's too late. About Cyclerion Therapeutics Stock (NASDAQ:CYCN)Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Read More CYCN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYCN Stock News HeadlinesJune 11, 2024 | americanbankingnews.comCyclerion Therapeutics (NASDAQ:CYCN) Trading Down 10.2%May 8, 2024 | investorplace.comCYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q1 2024June 18, 2024 | Weiss Ratings (Ad)Reclusive millionaire’s final warning about AmericaThis crisis that's likly to begin in this country — before the election — could be bigger and more destructive than any crisis I've ever seen. That's why, no matter what you do, make sure you watch my short video and learn the three steps you need to take right now.April 28, 2024 | benzinga.comSage Therapeutics Stock (NASDAQ:SAGE), Quotes and News SummaryApril 21, 2024 | morningstar.comCyclerion Therapeutics Inc Ordinary Shares CYCNApril 5, 2024 | investorplace.comCYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q4 2023March 6, 2024 | investing.comCyclerion Therapeutics Inc (CYCN)February 29, 2024 | uk.finance.yahoo.comCyclerion Therapeutics, Inc. (CYCN)June 18, 2024 | Weiss Ratings (Ad)Reclusive millionaire’s final warning about AmericaThis crisis that's likly to begin in this country — before the election — could be bigger and more destructive than any crisis I've ever seen. That's why, no matter what you do, make sure you watch my short video and learn the three steps you need to take right now.February 23, 2024 | benzinga.comCyclerion Therapeutics Stock (NASDAQ:CYCN) Dividends: History, Yield and DatesDecember 4, 2023 | msn.comCyclerion Therapeutics appoints Graul as PresidentNovember 30, 2023 | finance.yahoo.comCyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge InnovatorNovember 28, 2023 | finance.yahoo.comCyclerion Therapeutics' Market Cap Drops To US$5.0m Leaving Insiders With LossesJuly 31, 2023 | finance.yahoo.comTisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion AssetsJune 30, 2023 | ca.finance.yahoo.comCYCN - Cyclerion Therapeutics, Inc.June 2, 2023 | finanznachrichten.deCyclerion Therapeutics, Inc.: Cyclerion Regains Compliance with Nasdaq Minimum Bid Price RequirementJune 1, 2023 | msn.comCyclerion Therapeutics in compliance with Nasdaq minimum bid price ruleMay 16, 2023 | finanznachrichten.deCyclerion Therapeutics, Inc.: Cyclerion Announces Reverse Stock SplitMay 15, 2023 | msn.comCyclerion announces 1 for 20 reverse stock splitMay 12, 2023 | finance.yahoo.comCyclerion Therapeutics to Sell Assets for $81M, CEO Transition To New Spin-Off Private Company Established By Shareholders, New InvestorsMay 12, 2023 | finanznachrichten.deCyclerion Therapeutics, Inc.: Cyclerion Announces Corporate Updates and Q1 2023 Financial ResultsMay 12, 2023 | msn.comCyclerion Therapeutics down 6% on spin off agreementMay 11, 2023 | finance.yahoo.comCyclerion Announces Corporate Updates and Q1 2023 Financial ResultsMay 11, 2023 | finance.yahoo.comCyclerion Announces Definitive Agreement for Zagociguat and CY3018April 3, 2023 | finanznachrichten.deCyclerion Therapeutics, Inc.: Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment AgreementMarch 27, 2023 | marketwatch.comCyclerion Gets FDA Orphan Designation for Zagociguat in Mitochondrial Diseases >CYCNMarch 23, 2023 | finanznachrichten.deCyclerion Therapeutics, Inc.: Cyclerion Reports Corporate Update and Full Year 2022 Financial ResultsSee More Headlines Receive CYCN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyclerion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today6/18/2024Next Earnings (Estimated)7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CYCN CUSIPN/A CIK1755237 Webwww.cyclerion.com Phone(857) 327-8778FaxN/AEmployees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,260,000.00 Net MarginsN/A Pretax Margin-123.19% Return on Equity-77.93% Return on Assets-61.09% Debt Debt-to-Equity RatioN/A Current Ratio4.17 Quick Ratio4.17 Sales & Book Value Annual Sales$1.62 million Price / Sales4.78 Cash FlowN/A Price / Cash FlowN/A Book Value$4.62 per share Price / Book0.62Miscellaneous Outstanding Shares2,710,000Free Float2,355,000Market Cap$7.75 million OptionableNo Data Beta1.85 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Regina Graul Ph.D.PresidentMs. Rhonda M. Chicko (Age 58)Chief Financial Officer Dr. Todd Milne Ph.D.Senior Vice President of External InnovationMs. Jessica RennekampAssociate Director of Corporate CommunicationsKey CompetitorsObsEvaNASDAQ:OBSVChembio DiagnosticsNASDAQ:CEMIViracta TherapeuticsNASDAQ:VIRXAprea TherapeuticsNASDAQ:APREBriaCell TherapeuticsNASDAQ:BCTXView All CompetitorsInsidersTerrance McguireSold 8 sharesTotal: $27.20 ($3.40/share)View All Insider Transactions CYCN Stock Analysis - Frequently Asked Questions How have CYCN shares performed in 2024? Cyclerion Therapeutics' stock was trading at $3.35 on January 1st, 2024. Since then, CYCN shares have decreased by 14.6% and is now trading at $2.86. View the best growth stocks for 2024 here. When is Cyclerion Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, July 26th 2024. View our CYCN earnings forecast. How were Cyclerion Therapeutics' earnings last quarter? Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) issued its quarterly earnings data on Tuesday, May, 7th. The company reported ($0.62) earnings per share for the quarter. When did Cyclerion Therapeutics' stock split? Shares of Cyclerion Therapeutics reverse split on the morning of Tuesday, May 16th 2023. The 1-20 reverse split was announced on Tuesday, May 16th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 16th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Cyclerion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclerion Therapeutics investors own include Fulcrum Therapeutics (FULC), Ovid Therapeutics (OVID), Spectrum Pharmaceuticals (SPPI), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Xeris Biopharma (XERS), Abeona Therapeutics (ABEO), ACADIA Pharmaceuticals (ACAD), Aimmune Therapeutics (AIMT) and Celldex Therapeutics (CLDX). Who are Cyclerion Therapeutics' major shareholders? Cyclerion Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Cyclerion Therapeutics? Shares of CYCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CYCN) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclerion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclerion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.